FOCUS:Focus On Coronary Unstable Syndromes
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00268619|
Recruitment Status : Completed
First Posted : December 22, 2005
Last Update Posted : January 11, 2011
- To demonstrate that the acute administration of ramipril will control the inflammation process in patients with high-risk Acute Coronary Syndrome (ACS) as assessed by the high sensitivity C-reactive protein blood levels.
- To demonstrate that the normalization of blood glucose levels with intravenous insulin will improve the inflammation process during the acute phase of an ACS as assessed by Tumor necrosis factor alpha blood levels.
|Condition or disease||Intervention/treatment||Phase|
|Myocardial Ischemia||Drug: Ramipril||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Intervention Model:||Parallel Assignment|
|Official Title:||A Placebo-controlled, Double-blind, Randomized, Multicenter Study of Ramipril 5 and 10 mg Capsules and Insulin Infusion in Subjects With Unstable Coronary Syndromes|
|Study Start Date :||June 2004|
|Actual Primary Completion Date :||July 2005|
- To assess the highly specific C-reactive protein (hsCRP) blood levels [ Time Frame: during the study conduct ]
- To assess the tumor necrosing factor alpha (TNFα) blood levels [ Time Frame: during the study conduct ]
- TEAEs collection [ Time Frame: From the signature of the informed consent up to the end of the study ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00268619
|Study Director:||Stan Glezer||Sanofi|